SEARCH

SEARCH BY CITATION

References

  • 1
    Bandy U. Hepatitis C virus (HCV): a silent epidemic. Med Health R I 1999; 82: 223224.
  • 2
    Vong S, Bell BP. Chronic liver disease mortality in the United States, 1990-1998. HEPATOLOGY 2004; 39: 476483.
  • 3
    Fusconi M, Lenzi M, Ballardini G, Miniero R, Cassani F, Zauli D, et al. Anti-HCV testing in autoimmune hepatitis and primary biliary cirrhosis. Lancet 1990; 336: 823.
  • 4
    Quaranta JF, Tran A, Regnier D, Letestu R, Beusnel C, Fuzibet JG, et al. High prevalence of antibodies to hepatitis C virus (HCV) in patients with anti-thyroid autoantibodies. J Hepatol 1993; 18: 136138.
  • 5
    Johnson RJ, Gretch DR, Yamabe H, Hart J, Bacchi CE, Hartwell P, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328: 465470.
  • 6
    Divano MC, Parodi A, Rebora A. Anti-GOR antibodies in lichen planus. Dermatology 1994; 188: 205206.
  • 7
    Mayo MJ. Extrahepatic manifestations of hepatitis C infection. Am J Med Sci 2003; 325: 135148.
  • 8
    Seelig R, Renz M, Bunger G, Schroter H, Seelig HP. Anti-LKM-1 antibodies determined by use of recombinant P450 2D6 in ELISA and western blot and their association with anti-HCV and HCV-RNA. Clin Exp Immunol 1993; 92: 373380.
  • 9
    Obermayer-Straub P, Manns MP. Hepatitis C and D, retroviruses and autoimmune manifestations. J Autoimmun 2001; 16: 275285.
  • 10
    Muratori P, Muratori L, Verucchi G, Attard L, Bianchi FB, Lenzi M. Non-organ-specific autoantibodies in children with chronic hepatitis C: clinical significance and impact on interferon treatment. Clin Infect Dis 2003; 37: 13201326.
  • 11
    Muratori P, Muratori L, Guidi M, Granito A, Susca M, Lenzi M, et al. Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C. Clin Infect Dis 2005; 40: 501507.
  • 12
    Manns MP, Johnson EF, Griffin KJ, Tan EM, Sullivan KF. Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1. J Clin Invest 1989; 83: 10661072.
  • 13
    Gueguen M, Yamamoto AM, Bernard O, Alvarez F. Anti-liver-kidney microsome antibody type 1 recognizes human cytochrome P450 db1. Biochem Biophys Res Commun 1989; 159: 542547.
  • 14
    Yamamoto AM, Cresteil D, Homberg JC, Alvarez F. Characterization of anti-liver-kidney microsome antibody (anti-LKM1) from hepatitis C virus-positive and -negative sera. Gastroenterology 1993; 104: 17621767.
  • 15
    Parez N, Herzog D, Jacqz-Aigrain E, Homberg JC, Alvarez F. Study of the B cell response to cytochrome P450IID6 in sera from chronic hepatitis C patients. Clin Exp Immunol 1996; 106: 336343.
  • 16
    Enshell-Seijffers D, Denisov D, Groisman B, Smelyanski L, Meyuhas R, Gross G, et al. The mapping and reconstitution of a conformational discontinuous B-cell epitope of HIV-1. J Mol Biol 2003; 334: 87101.
  • 17
    Barlow DJ, Edwards MS, Thornton JM. Continuous and discontinuous protein antigenic determinants. Nature 1986; 322: 747748.
  • 18
    Vitozzi S, Lapierre P, Djilali-Saiah I, Alvarez F. Autoantibody detection in type 2 autoimmune hepatitis using a chimera recombinant protein. J Immunol Methods 2002; 262: 103110.
  • 19
    Czaja AJ, Doherty DG, Donaldson PT. Genetic bases of autoimmune hepatitis. Dig Dis Sci 2002; 47: 21392150.
  • 20
    Bogdanos DP, Lenzi M, Okamoto M, Rigopoulou EI, Muratori P, Ma Y, et al. Multiple viral/self immunological cross-reactivity in liver kidney microsomal antibody positive hepatitis C virus infected patients is associated with the possession of HLA B51. Int J Immunopathol Pharmacol 2004; 17: 8392.
  • 21
    Purcell RH. Hepatitis C (Flaviviridae). In: Encyclopedia of Virology. 2nd ed. New York: Webster AGeRG, 1999: 657663.
  • 22
    Amar-Costesec A, Beaufay H, Wibo M, Thines-Sempoux D, Feytmans E, Robbi M, et al. Analytical study of microsomes and isolated subcellular membranes from rat liver. II. Preparation and composition of the microsomal fraction. J Cell Biol 1974; 61: 201212.
  • 23
    Spector DL, Goldman RD, Leinwand LA. Cells: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1998: 72.172.74.
  • 24
    Lewis DF. Homology modelling of human CYP2 family enzymes based on the CYP2C5 crystal structure. Xenobiotica 2002; 32: 305323.
  • 25
    Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 1997; 18: 27142723.
  • 26
    Beland K, Lapierre P, Marceau G, Alvarez F. Anti-LC1 autoantibodies in patients with chronic hepatitis C virus infection. J Autoimmun 2004; 22: 159166.
  • 27
    Rowley MJ, Scealy M, Whisstock JC, Jois JA, Wijeyewickrema LC, Mackay IR. Prediction of the immunodominant epitope of the pyruvate dehydrogenase complex E2 in primary biliary cirrhosis using phage display. J Immunol 2000; 164: 34133419.
  • 28
    Rizzetto M, Swana G, Doniach D. Microsomal antibodies in active chronic hepatitis and other disorders. Clin Exp Immunol 1973; 15: 331344.
  • 29
    Lenzi M, Ballardini G, Fusconi M, Cassani F, Selleri L, Volta U, et al. Type 2 autoimmune hepatitis and hepatitis C virus infection. Lancet 1990; 335: 258259.
  • 30
    Czaja AJ, Taswell HF, Rakela J, Schimek CM. Frequency and significance of antibody to hepatitis C virus in severe corticosteroid-treated autoimmune chronic active hepatitis. Mayo Clin Proc 1991; 66: 572582.
  • 31
    Lapierre P, Herzog D, Alvarez F. Autoepitopes in Hepatitis C. In: RizzettoM, ed. Proceedings of the IX triennial International Symposium on Viral Hepatitis and Liver disease: Edizioni Minerva Medica, 1997: 460462.
  • 32
    Kerkar N, Ma Y, Hussain M, Muratori L, Targett C, Williams R, et al. A novel assay for detecting antibodies to cytochrome P4502D6, the molecular target of liver kidney microsomal antibody type 1. J Immunol Methods 1999; 223: 227235.
  • 33
    Kerkar N, Choudhuri K, Ma Y, Mahmoud A, Bogdanos DP, Muratori L, et al. Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J Immunol 2003; 170: 14811489.
  • 34
    Sugimura T, Obermayer-Straub P, Kayser A, Braun S, Loges S, Alex B, et al. A major CYP2D6 autoepitope in autoimmune hepatitis type 2 and chronic hepatitis C is a three-dimensional structure homologous to other cytochrome P450 autoantigens. Autoimmunity 2002; 35: 501513.
  • 35
    Yamamoto AM, Cresteil D, Boniface O, Clerc FF, Alvarez F. Identification and analysis of cytochrome P450IID6 antigenic sites recognized by anti-liver-kidney microsome type-1 antibodies (LKM1). Eur J Immunol 1993; 23: 11051111.
  • 36
    Parmley SF, Smith GP. Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene 1988; 73: 305318.
  • 37
    Penin F, Brass V, Appel N, Ramboarina S, Montserret R, Ficheux D, et al. Structure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5A. J Biol Chem 2004; 279: 4083540843.
  • 38
    Yao N, Reichert P, Taremi SS, Prosise WW, Weber PC. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure Fold Des 1999; 7: 13531363.
  • 39
    Gibrat JF, Madej T, Bryant SH. Surprising similarities in structure comparison. Curr Opin Struct Biol 1996; 6: 377385.
  • 40
    Shindyalov IN, Bourne PE. Protein structure alignment by incremental combinatorial extension (CE) of the optimal path. Protein Eng 1998; 11: 739747.
  • 41
    Kishore R. Beta-Ala containing peptides: potentials in design and construction of bioactive peptides and protein secondary structure mimics. Curr Protein Pept Sci 2004; 5: 435455.
  • 42
    Honda S, Yamasaki K, Sawada Y, Morii H. 10 residue folded peptide designed by segment statistics. Structure (Camb) 2004; 12: 15071518.
  • 43
    Bortolotti F, Vajro P, Balli F, Giacchino R, Crivellaro C, Barbera C, et al. Non-organ specific autoantibodies in children with chronic hepatitis C. J Hepatol 1996; 25: 614620.
  • 44
    Gregorio GV, Pensati P, Iorio R, Vegnente A, Mieli-Vergani G, Vergani D. Autoantibody prevalence in children with liver disease due to chronic hepatitis C virus (HCV) infection. Clin Exp Immunol 1998; 112: 471476.
  • 45
    Bortolotti F, Muratori L, Jara P, Hierro L, Verucchi G, Giacchino R, et al. Hepatitis C virus infection associated with liver-kidney microsomal antibody type 1 (LKM1) autoantibodies in children. J Pediatr 2003; 142: 185190.
  • 46
    Muratori L, Lenzi M, Cataleta M, Giostra F, Cassani F, Ballardini G, et al. Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C. J Hepatol 1994; 21: 199203.
  • 47
    Todros L, Saracco G, Durazzo M, Abate ML, Touscoz G, Scaglione L, et al. Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes. HEPATOLOGY 1995; 22: 13741378.
  • 48
    Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 1991; 88: 13701378.
  • 49
    Bogdanos DP, Choudhuri K, Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver 2001; 21: 225232.